Oxaliplatin for the treatment of ovarian cancer

Bibliography

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10–29
   PubMed Web of Science ®Google Scholar
• Thigpen T, Vance R, Puneky L, et al. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol 1994;55(3 Pt 2):S97
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194–200
   PubMed Web of Science ®Google Scholar
• Du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320–30
   PubMed Web of Science ®Google Scholar
• Herzog TJ. The current treatment of recurrent ovarian cancer. Curr Oncol Rep 2006;8:448–54
   PubMedGoogle Scholar
• Markman M. Optimal management of recurrent ovarian cancer. Int J Gynecol Cancer 2009;19(Suppl 2):S40–3
   PubMed Web of Science ®Google Scholar
• Burchenal J, Irani G, Kern K, et al. 1, 2-diaminocyclohexane platinum derivatives of potential clinical values. In: Mathé G, Muggia F, editor. Recent results in cancer research. Cancer chemo and immuno-pharmacology. 1st edition. Springer-Verlag; Berlin: 1980
   Google Scholar
• Vermorken J. The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer. Int J Gynecol Cancer 2001;11(1):21–30
   PubMed Web of Science ®Google Scholar
• Taylor SE, Beck TL, Krivak TC, et al. Oxaliplatin salvage for recurrent ovarian cancer: a single institution’s experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity. Gynecol Oncol 2014;134:68–72
   PubMed Web of Science ®Google Scholar
• FDA Approval for Oxaliplatin. Available from: www.cancer.gov/cancertopics/druginfo/fda-oxaliplatin
   Google Scholar
• Stein A, Arnold D. Oxaliplatin: a review of approved uses. Expert Opin Pharmacother 2012;13(1):125–37
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology, Ovarian Cancer, version 1. 2015. Available from: http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf
   Google Scholar
• Ibrahim A, Hirschfeld S, Cohen MH, et al. FDA drug approval summaries: oxaliplatin. Oncologist 2004;9:8–12
   PubMed Web of Science ®Google Scholar
• Boulikas T, Pantos A, Bellis E, et al. Designing platinum compounds in cancer: structures and mechanisms. Cancer Ther 2007;5:537–83
   Google Scholar
• Ortuzar W, Paull K, Rixe O, et al. Comparison of the activity of cisplatin (CP) and oxaliplatin (OXALI) alone or in combination in parental and drug resistant sublines. Proc Am Assoc Cancer Res 1994;35:332
   Google Scholar
• Mathe´ G, Kidani Y, Noji M, et al. Antitumor activity of l-OHP in mice. Cancer Letter 1985;27(2):135–43
   PubMed Web of Science ®Google Scholar
• Soulié P, Bensmaine A, Garrino C, et al. Oxaliplatin/cisplatin(L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer 1997;33:1400–6
   PubMed Web of Science ®Google Scholar
• Delaloge S, Laadem A, Taamma A, et al. Pilot study of the paclitaxel, oxaliplatin,and cisplatin combination in patients with advanced/recurrent ovarian cancer. Am J Clin Oncol 2000;23(6):569–74
   PubMed Web of Science ®Google Scholar
• Aebi S, Kurdihaidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996;53:3087–90
   Google Scholar
• Fink D, Nebel S, Norris PS, et al. Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer 1998;77:741–6
   PubMed Web of Science ®Google Scholar
• Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol 2011;18(1):18–25
   PubMed Web of Science ®Google Scholar
• Takimoto CH, Graham MA, Lockwood G, et al. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res 2007;13(16):4832–9
   PubMed Web of Science ®Google Scholar
• Allain P, Heudi O, Cailleux A, et al. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab Dispos 2000;28:1379–84
   PubMed Web of Science ®Google Scholar
• Caussanel JP, Levi F, Brienza S, et al. Phase I trial of 5-day continous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990;82:1046–50
   PubMed Web of Science ®Google Scholar
• Extra JM, Espie M, Calvo F. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990;25:299–303
   PubMed Web of Science ®Google Scholar
• Mathe G, Kidani Y, Triana K, et al. A phase I trial of trans-1-diaminocyclohexaneoxalato-platinum (1-OHP). Biomed Pharmacother 1986;40:372–6
   PubMed Web of Science ®Google Scholar
• Misset JL, Vennin PH, Chollet PH, et al. Multicenter phase II—III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients. Ann Oncol 2001;12(10):1411–15
   PubMed Web of Science ®Google Scholar
• Herzog TJ, Monk BJ, Rose PG, et al. A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. Gynecol Oncol 2014;132:517–25
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365(26):2473–83
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484–96
   PubMed Web of Science ®Google Scholar
• Malander S, Rambech E, Kristoffersson U, et al. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol 2006;101(2):238–43
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Kai M, Hemmi H, et al. A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. Br J Cancer 2001;85(7):1064–9
   PubMed Web of Science ®Google Scholar
• Helleman J, van Staveren IL, Winand NM, et al. Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer 2006;6:201
   PubMed Web of Science ®Google Scholar
• Dieras V, Bougnoux P, Petit T, et al. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin taxane-pretreated ovarian cancer patients Annal Oncol. 2002;13:258–66
   Google Scholar
• Misset JL, Kidani Y, Gastiaburu C, et al. Oxalatoplatinum (L-OHP):experimental and clinical studies. In: editor. Howell S, Platinum and other Metal Coordination Compounds in Cancer Chemotherapy. Plenum Press; New York: 1991
   Google Scholar
• Chollet P, Bensmaine A, Brienza S, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996;7:1065–70
   PubMed Web of Science ®Google Scholar
• Piccart M, Green J, Lacave A, et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 2000;18:1193–202
   PubMed Web of Science ®Google Scholar
• Vermorken J, Gore M, Perren T, et al. Multicenter randomized Phase II study of oxaliplatin (OXA) or topotecan (TOPO) in platinum pretreated epithelial ovarian cancer (EOC) patients. Proc AmSoc Clin Oncol 2001;20:212a
   Google Scholar
• Recchia F, Saggio G, Amiconi G, et al. A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer. Gynecol Oncol 2007;106:164–9
   PubMed Web of Science ®Google Scholar
• Nicoletto MO, Bertorelle R, Borgato L, et al. Family history of cancer rather than p53 status predicts efficacy of pegylated liposomal doxorubicin and oxaliplatin in relapsed ovarian cancer. Int J Gynecol Cancer 2009;19(6):1022–8
   PubMed Web of Science ®Google Scholar
• Della Palma M, Lombardi G, Donach ME, et al. Tolerability of PLD/Oxaliplatin regimen in recurrent ovarian cancer patients with previous fragility to carboplatin/Paclitaxel treatment. Am J Clin Oncol 2011;34:305–8
   PubMed Web of Science ®Google Scholar
• Mavroudis D, Pappas P, Kouroussis C, et al. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Ann Oncol 2003;14:304–12
   PubMed Web of Science ®Google Scholar
• Raspagliesi F, Zanaboni F, Vecchione F, et al. Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane. Oncology 2004;67:376–81
   PubMed Web of Science ®Google Scholar
• Germano D, Rosati G, Manzione L. Gemcitabine combined with oxaliplatin (GEMOX) as salvage treatment in elderly patients with advanced ovarian cancer refractory or resistant to platinum: a single institution experience. J Chemother 2007;19:577–81
   PubMed Web of Science ®Google Scholar
• Harnett P, Buck M, Beale P, et al. Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian ad New Zealand Gynecological Oncology Group study. Int J Gynecol Cancer 2007;17:359–66
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Weber B, Cretin J, et al. Gemcitabine-oxaliplatin for ovarian cancer resistant to taxaneplatinum treatment: a phase II study from the GINECO group. Br J Cancer 2009;100:601–7
   PubMed Web of Science ®Google Scholar
• Kalykaki A, Papakotoulas P, Tsousis S, et al. Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Anticancer Res 2008;28:495–500
   PubMed Web of Science ®Google Scholar
• Vici P, Sergi D, Pizzuti L, et al. Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients. J Exp Clin Cancer Res 2013;32(1):49
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Takano M, Oda K, et al. Weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with recurrent and refractory ovarian cancer. Int J Gynecol Cancer 2013;23:355–60
   PubMed Web of Science ®Google Scholar
• Faivre S, Kalla S, Cvitkovic E, et al. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate use experience. Ann Oncol 1999;10:1125–8
   PubMed Web of Science ®Google Scholar
• Viens P, Petit T, Yovine A, et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann Oncol 2006;17:429–36
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Ludovisi M, De Vincenzo R, et al. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Annal Oncol 2007;18:1348–53
   PubMed Web of Science ®Google Scholar
• Seliger G, Mueller LP, Kegel T, et al. Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer. Int J Gynecol Cancer 2009;19:1446–53
   Google Scholar
• Salah-Eldin MA, Wahba HA, Halim AA. Biweekly peglated liposomal doxorubicin/oxaliplatin for ovarian cancer resistant to taxane-platinum treatment: a phase II study. Indian J Cancer 2012;49(1):169–75
   PubMed Web of Science ®Google Scholar
• Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361(9375):2099–06
   PubMed Web of Science ®Google Scholar
• Syrigou E, Triantafyllou O, Makrilia N, et al. Acute hypersensitivity reactions to chemotherapy agents: an overview. Inflamm Allergy Drug Targets 2010;9(3):206–13
   PubMedGoogle Scholar
• Makrilia N, Syrigou E, Kaklamanos I, et al. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs published online 2010 doi:10.1155/2010/207084
   Google Scholar
• Markman M, Hsiesh F, Zanotti K, et al. Initial experience with novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. J Cancer Res Clin Oncol 2004;130:25–8
   PubMed Web of Science ®Google Scholar
• Abe A, Ikawa H, Ikawa S. Desensitization treatment with cisplatin after carboplatin hypersensitivity reaction in gynecologic cancer. J Med Invest 2010;57:163–7
   PubMedGoogle Scholar
• Ottaiano A, Tambaro R, Greggi S, et al. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma. Anticancer Res 2003;23:3465–8
   PubMed Web of Science ®Google Scholar
• Kim BH, Bradley T, Tai J, et al. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology 2009;76:231–8
   PubMed Web of Science ®Google Scholar
• Markman M. Hypersensitivity reactions: an increasingly recognized toxicity of platinum agents. Oncology 2009;76:229–30
   PubMed Web of Science ®Google Scholar
• Taylor SE, Beck TL, Krivak TC, et al. Oxaliplatin salvage for recurrent ovarian cancer: a single institution’s experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity. Gynecol Oncol 2014;134:68–72
   PubMed Web of Science ®Google Scholar
• Kolomeyevskaya NV, Shashikant BL, Miller A, et al. Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to carboplatin. Int J Gynecol Cancer 2015;25(1):42–8
   PubMed Web of Science ®Google Scholar
• Cassidy J, Misset J-L. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002;29(5 Suppl 15):11–20
   PubMed Web of Science ®Google Scholar
• Saif M W, Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 2005;1(4):249–58
   PubMedGoogle Scholar
• Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003;4(15):5–13
   Web of Science ®Google Scholar
• Adelsberger H, Quasthoff S, Grosskreutz J, et al. The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons. Euro J Pharmacol 2000;406:25–32
   PubMed Web of Science ®Google Scholar